<i>PLCXD3-ALK</i>, a novel <i>ALK</i> rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors.

ABSTRACT:

Background

Lung cancer is the leading cause of cancer-related death worldwide, of which anaplastic lymphoma kinase fusion positive (ALK ⁺) non-small cell lung cancer (NSCLC) accounts for 3-7. Here, we identified a new fusion gene PLCXD3-ALK (P1, A19) from a patient with advanced lung squamous cell carcinoma (LUSC) by next-generation sequencing (NGS). We aimed to evaluate its oncogenic potential by performing functional studies in vitro and tumorigenicity in vivo of this fusion protein.

Methods

We performed functional experiments in NIH-3T3 cells with stable expression of PLCXD3-ALK including soft agar colony formation assay, cell proliferation and viability assays, and transwell assay. The activation of downstream pathways and th

SUBMITTER: Chen K 

PROVIDER: S-EPMC11833567 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature